Stock Market Reviews

Read and share opinions on SNY (Sanofi) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang
  Dec 30, 2025
• Where is Sanofi (SNY) Headed According to Wall Street?
  Dec 30, 2025
• Delayed MS Decision and Trial Miss Add to Sanofi’s R&D Challenges
  Dec 29, 2025
• Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)
  Dec 28, 2025
• Company News for Dec 26, 2025
  Dec 26, 2025

SNY News

• Where is Sanofi (SNY) Headed According to Wall Street?
  Sanofi (NASDAQ:SNY) is one of the best affordable healthcare stocks to buy now. Sanofi (NASDAQ:SNY) announced on December 24 an agreement to acquire Dynavax Technologies Corporation, which is a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. Dynavax’s adult hepatitis B vaccine HEPLISAV-B is marketed in […]
  Dec 30, 2025
• Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection
  The deal adds hepatitis B and early-stage shingles vaccines as Sanofi faces pipeline pressure from tolebrutinib setback.
  Dec 29, 2025
• Delayed MS Decision and Trial Miss Add to Sanofi’s R&D Challenges
  Sanofi (NASDAQ:SNY) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be delayed again. On the same day, the company also disclosed weaker-than-expected results from a late-stage clinical study, adding to a difficult stretch […]
  Dec 29, 2025
• Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
  Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the submission of its seventh annual Development Safety Update Report (DSUR) to the
  Dec 29, 2025
• Sanofi buys hep B vaccine maker for $2.2bn
  Sanofi is adding a hepatitis B vaccine and shingles vaccine candidate to its portfolio via the deal.
  Dec 29, 2025
• Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)
  Sanofi (NASDAQ:SNY) is one of the Best Affordable Stocks to Buy According to Analysts. On December 24, Sanofi (NASDAQ:SNY) announced entering into a definitive agreement to acquire Dynavax Technologies Corporation (NASDAQ:DVAX), a company that has a marketed hepatitis B vaccine and a differentiated shingles vaccine candidate. Management noted that the acquisition aligns with the company’s […]
  Dec 28, 2025
• Company News for Dec 26, 2025
  Companies In The News Are: NVDA, NKE, AAPL, DVAX, SNY, INTC.
  Dec 26, 2025
• Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger
  We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Dynavax Technologies Corp. (NASDAQ:DVAX) is one of the best performers on Wednesday. Dynavax soared by 38.19 percent on Wednesday to close at $15.38 apiece as investors took heart from news that it was set to be acquired by Sanofi for $2.2 billion. In a […]
  Dec 25, 2025
• Top Midday Gainers
  Omeros (OMER) said Wednesday the US Food and Drug Administration has approved Yartemlea to treat hem
  Dec 24, 2025
• Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
  SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
  Dec 24, 2025
• BP to sell 65% of Castrol stake, Sanofi's $2.2B deal for Dynavax
  Yahoo Finance executive editor Brian Sozzi tracks several of the day's top trending stock tickers, including BP (BP) selling 65% of its stake in Castrol automotive lubricant business to Stonepeak, Sanofi (SNY) agreeing to acquire hepatitis B vaccine maker Dynavax Technologies (DVAX) in a $2.2 billion deal, and UiPath (PATH) is scheduled to begin trading on the S&P Midcap 400 index (^SP400). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.
  Dec 24, 2025
• Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio
  Deal adds approved hepatitis B shot and early-stage shingles vaccine to Sanofi's pipeline.
  Dec 24, 2025
• Stocks Down Pre-Bell Ahead of Shortened Trading Session
  The main US stock measures were trending lower in Wednesday's premarket activity as investors prepar
  Dec 24, 2025
• Why Dynavax Stock Soared Today
  A healthcare titan wants to buy the biotech's vaccines.
  Dec 24, 2025
• How major US stock indexes fared Wednesday, 12/24/2025
  US stocks drifted higher to more records on a holiday-shortened day of trading. The S&P 500 rose 0.3%. The Dow Jones Industrial Average climbed 0.6%, and the Nasdaq composite edged up 0.2%.
  Dec 24, 2025
• Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal
  All three major US stock indexes were edging higher in late-morning trading on Wednesday after initi
  Dec 24, 2025
• Xmas Eve Jobless Claims: Still Accommodating
  Despite today being Christmas Eve and markets closing at 1pm ET, we see new Weekly Jobless Claims numbers ahead of today's opening bell.
  Dec 24, 2025
• Equity Futures Hold Steady Pre-Bell as US Initial Jobless Claims Beat Analyst Range
  Traders continued to maintain caution during the holiday season as US equity futures stayed in a hol
  Dec 24, 2025
• FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
  Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
  Dec 24, 2025
• Sector Update: Health Care Stocks Rise Wednesday Afternoon
  Health care stocks were rising in recent early Wednesday afternoon trading, with the NYSE Health Car
  Dec 24, 2025
• Soft Weekly Jobless Claims Data
  Soft Weekly Jobless Claims Data.
  Dec 24, 2025
• KB Home downgrade, Costco upgraded: Wall Street's top analyst calls
  KB Home downgrade, Costco upgraded: Wall Street's top analyst calls
  Dec 24, 2025
• KB Home downgraded, Costco upgraded: Wall Street's top analyst calls
  KB Home downgraded, Costco upgraded: Wall Street's top analyst calls
  Dec 24, 2025
• Sanofi to Buy Dynavax to Boost Vaccines Business
  Sanofi agreed to buy Dynavax for about $2.2 billion, as the French drugmaker tries to expand a vaccines business currently anchored by its flu shot franchise. The announcement came after the US Food and Drug Administration surprisingly rejected Sanofi's experimental multiple sclerosis drug tolebrutinib. Bloomberg's Ashleigh Furlong reports.
  Dec 24, 2025
• Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Shortened Trading Week
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad
  Dec 24, 2025
• Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
  Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Dynavax), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and differentiated shingles vaccine candidate. The acquisition augments Sanofi’s presence in adult immunization by bringing together Dynavax’s vacc
  Dec 24, 2025
• Sanofi to Acquire Vaccine Maker Dynavax in $2.2 Billion Deal
  Sanofi (SNY) on Wednesday agreed to acquire infectious disease vaccine maker Dynavax Technologies (D
  Dec 24, 2025
• Biggest Mover Wednesday: Dynavax Stock Soars on $2.2 billion Acquisition Deal
  Sanofi Expands Its Vaccine Business With Dynavax Acquisition
  Dec 24, 2025
• European Stocks Close Mixed in Wednesday Trading; Sanofi to Acquire Dynavax Technologies
  European stock markets closed mixed Wednesday as the Stoxx Europe 600 eased less than 0.1%, the FTSE
  Dec 24, 2025
• Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline
  Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Nasdaq: DVAX), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. The acquisition augments Sanofi's presence in adult immunization by bringing together Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach.
  Dec 24, 2025
• Sanofi (ENXTPA:SAN): Revisiting Valuation After a Recent Share Price Rebound
  Sanofi (ENXTPA:SAN) shares have quietly bounced about 2% this week, even though they are still down roughly 13% year to date. This invites a closer look at what the market is currently pricing in. See our latest analysis for Sanofi. The recent uptick, alongside a 90 day share price return of 3.42% and a milder 1 year total shareholder return of negative 6.44%, suggests sentiment is stabilising rather than surging as investors weigh steady earnings growth against past regulatory and pipeline...
  Dec 24, 2025
• Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
  Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adult patients. On December 15, 2025, Sanofi provided an update on the ongoing review which stated that: (i) FDA was expecting the review to go beyo
  Dec 24, 2025
• Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
  The French drugmaker is looking to dealmaking after some experimental drugs missed their goals in clinical studies or were turned down by regulators.
  Dec 24, 2025
• Sanofi To Buy Vaccine Maker Dynavax For $2.2 Billion
  Sanofi will buy vaccine maker Dynavax Technologies for $2.2 billion, or $15.50 a share, adding to its adult immunizations. Dynavax stock soared.
  Dec 24, 2025
• This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion.
  Sanofi has agreed to acquire vaccine maker Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value. Dynavax shareholders will receive $15.50 a share in the deal, a premium on the stock’s closing price of $11.13 on Tuesday. Shares of Dynavax spiked 39% to $15.42 on Wednesday.
  Dec 24, 2025
• Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying
  Sanofi will pay $2.2 billion for Dynavax Techologies as it looks to add another Hepatitis B and new shingles vaccines to its portfolio.
  Dec 24, 2025
• GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: With the Semaglutide Patent Expiring in 2026 Onwards, the Biosimilars Market is Expected to Grow Significantly
  The GLP-1 agonists market is set to skyrocket, reaching USD 170.75 billion by 2033, growing from USD 64.42 billion in 2025 at a CAGR of 13.0%. Driven by expanding indications, the market sees robust demand amid rising chronic conditions like obesity and diabetes. Patented products dominated the market in 2024, while biosimilars are projected to rise post-2026, following patent expiry. In 2024, home-care settings led the market by end user due to rising self-administration trends. The US helmed t
  Dec 23, 2025
• Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
  Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITPApproval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other ITP symptomsITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, December 23, 2025 – The European
  Dec 23, 2025
• Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
  Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%) Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized phase 3 study, and inhibits IL-4 and IL-13, two key and central driver
  Dec 23, 2025
• Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
  Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized Phase 3 trial, and inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation TARRYTOWN, N.Y. and PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmace
  Dec 23, 2025
• Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
  Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
  Dec 22, 2025
• Sanofi: Information concerning the total number of voting rights and shares - November 2025
  Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,438,854,192Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis
  Dec 22, 2025
• Trump reaches deal with 9 drug companies to lower prices
  President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.
  Dec 19, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t
  Dec 19, 2025
• Nine Drugmakers Strike Deals With Trump, With More to Come
  The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.
  Dec 19, 2025
• Is Sanofi Now an Opportunity After Recent Share Price Weakness?
  Wondering if Sanofi is quietly turning into a bargain while the market looks the other way? Let us dig into whether the current share price really reflects what this pharma heavyweight is worth. Despite a solid 5 year gain of 27.7%, the stock is down 1.8% over the last week, 6.3% over the last month, and 13.0% year to date, signaling a notable reset in expectations. Recently, investors have been weighing Sanofi's shifting strategic priorities and its evolving drug pipeline, which has...
  Dec 19, 2025
• Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases
  The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano
  Dec 19, 2025
• Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
  Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump’s four requests, establishing a framework for lower prices for patients in the US and a tariff-free accord for SanofiShowcases commitment to US manufacturing, innovation, and economic growth Paris, December 19, 2025. Sanofi today announced an agreement with President Donald J. Trump's Administration to help ensure American patients have access to more affor
  Dec 19, 2025
• Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
  Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.
  Dec 19, 2025
• More Drugmakers Reach Deals With White House to Lower Prices
  The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
  Dec 19, 2025
• SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
  Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
  Dec 18, 2025
• Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades
  We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Sanofi is among the most undervalued stocks. Between December 8 and December 10, 2025, SNY faced a series of analyst rating adjustments that tempered investor sentiment. The Fly reported on Monday, December 8, 2025, that J.P. Morgan downgraded SNY from […]
  Dec 17, 2025
• Press release: Availability of the Q4 2025 Aide memoire
  Availability of the Q4 2025 Aide memoire Paris, France – December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: Fourth quarter & full year 2025 results (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's f
  Dec 17, 2025
• Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
  Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi’s commitment to developing treatments for rare diseasesEfdoralprin alfa, an investigational restorative recombinant therapy, recently met all primary and key secondary endpoints in phase 2 head-to-head study versus a plasma-derived standard of care Paris, December 17, 2025. The European Medicines Agency (EMA) has granted orphan designat
  Dec 17, 2025
• Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
  Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA) class II-III obstructive hypertroph
  Dec 17, 2025
• Market update
  Press Release Paris – December 16, 2025 - EUROAPI announced today that its main shareholders, Sanofi and EPIC Bpifrance, have agreed to extend further the duration of their lock-up until December 18, 2026, subject to customary exceptions. This extension strengthens the stability of EUROAPI’s shareholding structure throughout the execution of its FOCUS-27 plan. Based on its latest forecast, EUROAPI also provided the following business update: In a deteriorated overall business environment, Full Y
  Dec 16, 2025
• SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
  Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
  Dec 16, 2025
• KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer
  MAHWAH, N.J., December 16, 2025--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025.
  Dec 16, 2025
• Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
  REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation and dermatitisEfficacy comparable to anti-IL-4/IL-13 antibody combination control with a favorable tolerability profile in preclinical modelsBeing advanced under a strategic partnership with Sanofi, where Recludix has the option to participate in a 50:50 U.S. profit/loss share SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE)
  Dec 16, 2025
• FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts
  The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged with $60 million in Series A funding.
  Dec 16, 2025
• Pharma M&A deal value up 31% YoY in 2025YTD amid return of mega-deals
  Large M&A transactions and bidding wars for Metsera and Avadel announced in H2 2025 reflect a need for large pharma companies to replenish pipelines through M&A ahead of looming patent cliffs.
  Dec 16, 2025
• Sanofi signs pair of billion-dollar biotech deals to bolster pipeline
  Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively.
  Dec 16, 2025
• ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
  ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced that it has entered into an exclusive worldwide license agreement with Sanofi, a multinational healthcare company, for the development and commercialization of ADEL-Y01, a potential first-in-class antibody therapy for Alzheimer's disease, and related backup compounds.
  Dec 15, 2025
• Sanofi, Dren Bio Collaborate on Next-Gen B-Cell Therapy for Autoimmune Diseases
  Sanofi (SNY) has entered a strategic collaboration with Dren Bio to develop a next-generation B-cell
  Dec 15, 2025
• Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
  SAN CARLOS, Calif., December 15, 2025--Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy.
  Dec 15, 2025
• Sanofi Says Primary Progressive Multiple Sclerosis Drug did not Meet Main Goal in a Phase 3 Trial
  Sanofi (SNY) said Monday its phase 3 trial of its experimental drug, tolebrutinib, did not meet the
  Dec 15, 2025
• Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
  Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed Paris, December 15, 2025. Sanofi anticipates that the review process for the ongoing US regulatory review of tolebrutinib in non-relapsing secondary progressive multiple sclerosis (nrSPMS) will extend beyond the previously communicated US
  Dec 15, 2025
• Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
  Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placeboThe safety profile of tolebrutinib was consistent with previous studies Paris, December 15, 2025. Results from the PERSEUS phase 3 study (clinical study identifier: NCT04458051) showed that tolebrutinib did not meet its pr
  Dec 15, 2025
• Sanofi Shares Fall After Multiple Sclerosis Drug Gets Hit by Double Setback
  A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn’t hit its main goal.
  Dec 15, 2025
• Stocks to Watch Monday: iRobot, EchoStar, Rocket Lab, Alibaba
  ↘️ iRobot (IRBT): The Roomba maker declared bankruptcy over the weekend. It said customer service and app functionality will continue normally during the restructuring. Shares tumbled more than 80% before the bell.
  Dec 15, 2025
• Sanofi MS drug hits two setbacks
  Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple sclerosis and is facing a delayed U.S. approval decision in another form of the disease.
  Dec 15, 2025
• Health Care Roundup: Market Talk
  Gain insight on Sanofi, Hikma Pharmaceuticals, and more in the latest Market Talks covering the health care sector.
  Dec 15, 2025
• Sanofi shares fall 6% after double setback for MS drug tolebrutinib
  The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.
  Dec 15, 2025
• Why Analysts Think Sanofi’s Story Is Shifting Even As Shares May Still Be Undervalued
  Sanofi’s latest fair value estimate has been nudged down from €106.26 to €105.20 as analysts factor in slightly softer revenue growth assumptions, even as the company’s overall risk profile remains largely unchanged at a similar discount rate. This modest reset reflects a more balanced view between the company’s long term growth ambitions and execution risks that could still influence how investors perceive its upside potential. Read on to see how you can stay ahead of these evolving fair...
  Dec 13, 2025
• Kymera's Eczema Drug Gets Fast Track Designation in the United States
  KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
  Dec 12, 2025
• Sanofi (SNY) Sees Slight Pessimism From Analysts
  We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) is a French pharmaceutical firm that has been at the center of several analysts’ attention lately. One such coverage came from Guggenheim on December 9th after the firm cut its stock rating to Neutral […]
  Dec 12, 2025
• Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
  Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a yearCablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medici
  Dec 11, 2025
• Why I Wouldn't Touch Novavax With a 10-Foot Pole
  This stock could be a wealth destroyer in the next five years.
  Dec 11, 2025
• Sanofi’s Bleeding-Disorder Treatments Get Approval in China
  Two treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.
  Dec 11, 2025
• Why Wall Street Analysts Are Closely Watching Sanofi (SNY)
  Sanofi (NASDAQ:SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has a ‘Buy’ or equivalent rating from the majority of the analysts covering the stock. With a one-year median price target of $61, the stock has an upside potential of 23.16%. According to TheFly, BofA reduced […]
  Dec 10, 2025
• JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105
  Sanofi (NASDAQ:SNY) is one of the best pharma stocks to invest in. Sanofi (NASDAQ:SNY) was downgraded to Neutral from Overweight by JPMorgan on December 8, with the firm also bringing the price target down to EUR 95 from EUR 105. The firm told investors that it is adjusting its ratings in the European pharma group to take […]
  Dec 10, 2025
• InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders
  SEATTLE & CAMBRIDGE, Mass., December 10, 2025--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a strategic equity investment and research collaboration with Sanofi. The agreement with Sanofi includes the right of first negotiation for InduPro’s bispecific PD-1 agonist program, which is currently in preclinical development for the treatment of autoimmune and inf
  Dec 10, 2025
• KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
  Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.
  Dec 9, 2025
• Sanofi (ENXTPA:SAN): Assessing Valuation After Recent Share Price Weakness
  Sanofi (ENXTPA:SAN) has been drifting lower recently, and that slide is starting to catch investors attention as they weigh short term weakness against long term growth in vaccines, immunology, and specialty care. See our latest analysis for Sanofi. At around $83.6, Sanofi’s recent pullback, including a negative year to date share price return and softer short term moves, contrasts with a still respectable five year total shareholder return that signals long term compounding is intact. If...
  Dec 9, 2025
• ​Sanofi (SNY) Completes the Acquisition of Vicebio
  ​Sanofi (NASDAQ:SNY) is one of the Cheap NASDAQ Stocks to Buy Now. On December 4, Sanofi (NASDAQ:SNY) announced the completion of the Vicebio acquisition. Vicebio is a clinical-stage biotechnology company focused on developing transformative multi-pathogen vaccines for respiratory viral infections. ​Management noted that this strategic acquisition brings Vicebio’s early-stage vaccine candidate for respiratory syncytial virus […]
  Dec 9, 2025
• Will Dupixent’s New Urticaria Approval Reshape Sanofi’s (ENXTPA:SAN) Biologics-Driven Growth Narrative?
  RegRegon Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above who do not respond adequately to standard antihistamines and are anti-IgE therapy naive. This approval broadens Dupixent’s use into a challenging allergic condition affecting more than 270,000 people in the EU, reinforcing its role within Sanofi’s biologics portfolio focused on inflammation and...
  Dec 9, 2025
• European Equities Traded in the US as ADRs Little Changed in Monday Trading
  European equities traded in the US as American depositary receipts were little changed late Monday m
  Dec 8, 2025
• Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?
  Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.
  Dec 8, 2025
• European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
  European equities traded in the US as American depositary receipts were tracking modestly higher lat
  Dec 5, 2025
• Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
  Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.
  Dec 5, 2025
• Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting
  Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term AYVAKIT® (avapritinib) use across the spectrum of systemic mastocytosis (SM), including indolent and advanced SM. AYVAKIT led to sustained symptom and quality-of-life benefits in indolent SM (ISM) after a median follow-up of more than three years, and extended survival rates in advanced SM after a median follow-up of more than four years. Across both forms of SM, AYVAKIT
  Dec 5, 2025
• Is Sanofi Now an Opportunity After Recent R and D and Portfolio Reshaping Moves?
  Wondering if Sanofi is quietly turning into a bargain, or if the market is already pricing it perfectly? Let us unpack what the current share price might really be telling you. Despite a solid long term track record, with the stock up 26.0% over five years and 7.2% over three years, recent moves have been softer, with shares down 1.5% over the last week, 2.0% over the past month, and 10.3% year to date, leaving the price around €84.57. Recent headlines around Sanofi have centered on its...
  Dec 4, 2025
• Press Release: Sanofi completes acquisition of Vicebio
  Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. The acquired vaccine candidate complements Sanofi’s position in respiratory vacci
  Dec 4, 2025
• LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes
  LONDON, December 04, 2025--LabGenius Therapeutics ("LabGenius"), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. Following the succes
  Dec 4, 2025
• ARWR: Multiple Data Readouts Ahead in 2026…
  By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Multiple Data Readouts Ahead in 2026 Following the recent approval of REDEMPLO ® for the treatment of patients with familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week
  Dec 1, 2025
• The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients
  Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent as a first-line treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and older who do not respond to antihistamines and are naive to anti-IgE therapy, based on positive Phase 3 clinical trial results. This marks the first innovation for CSU patients in Europe in over a decade and potentially opens access for approximately 270,000 eligible...
  Nov 28, 2025
• Deutsche Bank Maintains a Buy Rating on Sanofi (SNY)
  Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25, setting a €110 price target. The same day, Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of “moderate-to-severe chronic […]
  Nov 28, 2025
• European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gain 4% for Week
  European equities traded in the US as American depositary receipts were trending higher late Friday
  Nov 28, 2025
• Novavax’s R&D Shift and Sanofi Partnership Could Be a Game Changer for NVAX
  Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development strategy, particularly in collaboration with Sanofi. This pivot comes alongside an increased full-year 2025 adjusted revenue projection, reflecting a greater reliance on licensing and royalty revenues as product sales decline. We'll explore how Novavax’s emphasis on research partnerships and...
  Nov 26, 2025
• Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
  KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
  Nov 26, 2025
• European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
  European equities traded in the US as American depositary receipts were surging higher late Wednesda
  Nov 26, 2025
• Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation
  Sanofi stock dropped Wednesday after French authorities raided the drugmaker's Paris headquarters as part of a tax fraud investigation.
  Nov 26, 2025
• Dupixent gains chronic spontaneous urticaria indication in Europe
  The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.
  Nov 26, 2025
• SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
  Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
  Nov 25, 2025
• Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast
  Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results on November 6, emphasizing the company’s continuous strategic shift from a direct COVID-19 commercial operation to an R&D-focused company, especially in partnership with Sanofi. For the third quarter, Novavax, Inc. (NASDAQ:NVAX) reported total […]
  Nov 25, 2025
• Sanofi (ENXTPA:SAN) Valuation: Is the Recent Share Price Pullback a Long-Term Opportunity?
  Sanofi (ENXTPA:SAN) shares have edged slightly lower over the past week, giving investors pause as they reassess the stock’s recent performance. This moderation may prompt a closer look at valuation and fundamentals. See our latest analysis for Sanofi. Over the past year, Sanofi’s shares have faced some choppy momentum. The recent 7-day share price return is down 4.38%, and year-to-date the stock has shown an 8.87% decline, while the 1-year total shareholder return stands at -3.29%. Despite...
  Nov 25, 2025
• Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
  Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatmentDupixent, which inhibits IL4 and IL13, two key and central drivers of t
  Nov 25, 2025
• Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
  Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflammatory diseases in the EU TARRYTOWN, N.Y. and PARIS,
  Nov 25, 2025
• Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
  PASADENA, Calif., November 25, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results.
  Nov 25, 2025
• DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
  DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of a new peer-reviewed study in the Journal of Medical Internet Research (JMIR), a highly influential digital health journal, evaluating healthcare utilization and medical costs among Dario users compared to matched non-users receiving usual care. The study, "Effects of a Digital Health Intervention for Adults with Type 2 Diabetes Mellitus on Health Care
  Nov 24, 2025
• Viscosupplementation Market Competitive Landscape Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts
  The viscosupplementation market is projected to grow robustly, reaching US$ 10.16 billion by 2033 from US$ 4.66 billion in 2024, with a CAGR of 9.02% from 2025 to 2033. This minimally invasive treatment involves injecting hyaluronic acid derivatives into knee joints to alleviate osteoarthritis symptoms such as inflammation and pain while enhancing joint mobility. Major companies like Smith & Nephew, Roche, Sanofi, Chugai Pharmaceuticals, and others play a pivotal role in this expanding industry.
  Nov 24, 2025
• SANOFI WINS THE 2025 PRIX GALIEN CANADA INNOVATIVE PRODUCT AWARD
  Prix Galien Canada is proud to announce Sanofi as the recipient of the prestigious 2025 Innovative Product Award for the development and delivery of nirsevimab (Beyfortus), a groundbreaking monoclonal antibody approved for the prevention of lower respiratory tract infections caused by Respiratory Syncytial Virus (RSV) in newborns and infants.
  Nov 20, 2025
• This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.
  For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.
  Nov 20, 2025
• Does Sanofi’s Falling Share Price Reveal Opportunity Following R&D Pipeline Progress?
  Ever wondered if Sanofi is offering real value right now, or if the stock’s price is disguising hidden potential? Let’s explore what savvy investors are seeing beneath the surface. Sanofi stock has been on a bit of a rollercoaster lately, with a 4.6% decline over the last week, narrowing to a 0.7% decline over the past month, and sitting at an 8.9% decrease year-to-date, compared to a 24.3% increase over five years. Recent news has highlighted ongoing momentum in Sanofi’s R&D pipeline, from...
  Nov 19, 2025
• Head and Neck Squamous Cell Carcinoma Market Research Report 2025-2035: Sanofi, Sun Pharma, and Eli Lilly Lead Through the Development of New Drugs, Clinical Trials, Combination Treatment Strategies
  The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for targeted therapies. Key innovations like immunotherapies, precision medicine, and early detection biomarkers are reshaping the market landscape, improving patient outcomes, and driving therapy adoption. Developed and emerging markets see enhanced care accessibility, propelled by investments in cancer i
  Nov 19, 2025
• Autoimmunity BioSolutions Bolsters Leadership Team
  Autoimmunity BioSolutions (ABS), is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or "correct" elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor therapeutic response in autoimmune disease.
  Nov 19, 2025
• Pleural Effusion Market Research Report 2025-2035: Novatech, Sanofi, and Pfizer Lead Innovation Through Strategic Partnerships and R&D Expansion
  The global pleural effusion market is experiencing steady growth due to advancements in medical treatments and diagnostic tools, increased awareness of respiratory health, and a rising demand for effective management solutions. Key drivers include the development of advanced drainage systems, anti-inflammatory drugs, and minimally invasive treatments like thoracentesis and pleurodesis. As awareness of pleural effusion's risks increases, early detection and intervention remain crucial. Despite ch
  Nov 18, 2025
• Intestinal Fistula Market Analysis Report 2025-2035: Competition Intensifies as Sanofi and Novartis Drive Innovation Through Strategic Partnerships and Advanced Treatment Expansion
  The global intestinal fistula market is witnessing steady growth driven by advancements in medical treatments, increased awareness of gastrointestinal health, and rising demand for effective management of complex conditions. Innovations in biologics, nutrition therapies, and surgical techniques are reshaping the market landscape, enhancing patient outcomes. With growing healthcare spending and infrastructure in the U.S., Europe, and emerging economies, the market is set for expansion. Key player
  Nov 18, 2025
• Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
  Burlington, Massachusetts--(Newsfile Corp. - November 18, 2025) - Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, today announced a strategic investment from Sanofi Ventures, the venture arm of global healthcare leader Sanofi, and funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture. The new funds bring the total raised to $112 million and...
  Nov 18, 2025
• CING: Third Quarter Results
  By John Vandermosten, CFA NASDAQ:CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ:CING) reported third quarter 2025 results on November 13 th , 2025. No revenues were recorded and operating expense totaled $6.0 million. The new drug application (NDA) to the FDA was accepted and a PDUFA date of May 31 st , 2026 was given. Cingulate also saw changes in its management ranks as the
  Nov 17, 2025
• Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
  Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes (T1D), compared to placebo, in adults and children with stage 2 T1DIf approved, Teizeild would become the first disease-modifying T1D therapy in the EU Paris, November 14, 2025. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopte
  Nov 14, 2025
• Sanofi (ENXTPA:SAN) Is Up 5.7% After Dupixent’s Positive Phase 3 Results in AFRS—What's Changed
  Sanofi announced positive results from the pivotal Phase 3 LIBERTY-AFRS-AIMS trial showing Dupixent significantly improved outcomes for adults and children aged 6 years and older with allergic fungal rhinosinusitis (AFRS), and the FDA has granted priority review for a supplemental biologics license application in this indication. This marks the first-ever positive Phase 3 results specifically in AFRS and highlights potential expansion for Dupixent into a challenging-to-treat disease where...
  Nov 13, 2025
• Sanofi: Information concerning the total number of voting rights and shares – October 2025
  Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis
  Nov 13, 2025
• Why Analysts Are Rethinking Sanofi’s Outlook as Its Growth Narrative Evolves
  Sanofi’s stock narrative is shifting as analysts revise their consensus price target slightly downward, from $106.90 to $106.85. This minor adjustment reflects a careful reassessment of Sanofi’s prospects, taking into account both its steady fundamentals and evolving external conditions. Stay tuned to discover the factors driving these expectations and how you can stay up to date as the outlook continues to evolve. Analyst Price Targets don't always capture the full story. Head over to our...
  Nov 11, 2025
• Sanofi (ENXTPA:SAN): Exploring Whether Shares Trade Below Their True Value
  Sanofi (ENXTPA:SAN) has caught the attention of investors lately, especially as its stock has seen gradual movement over the past month. Shares are currently trading at €85.44, which reflects a subtle upward trend. See our latest analysis for Sanofi. While Sanofi’s share price has ticked up by 2.5% over the past month, a longer view tells a more measured story. The stock is still working to recapture ground lost earlier in the year, with a 6.8% dip in total shareholder return over the past...
  Nov 10, 2025
• Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%
  Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.
  Nov 8, 2025
• Novavax Inc (NVAX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial Challenges
  Novavax Inc (NVAX) focuses on innovation and partnerships amid financial hurdles, aiming for profitability by 2028.
  Nov 7, 2025
• Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
  NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
  Nov 7, 2025
• Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
  Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years and older compared to placebo Dupixent sBLA accepted for priority review by the U.S. FDA with a target action date of February 28, 2026 If approved, Dupixent would be the first and only medicine indicated specifically for AFRS, which would be its ninth FDA-approved indication AFRS is a chronic type
  Nov 7, 2025
• Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
  ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients aged 6 years and older compared to placeboDupixent sBLA accepted for priority review by the US FDA with a target acti
  Nov 7, 2025
• Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
  Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2025.
  Nov 6, 2025
• Rezurock® now covered in Quebec for people living with chronic graft-versus-host disease (GVHD)
  Sanofi is pleased to announce that Quebec has added Rezurock® (belumosudil tablets) to the list of medications covered by the Régie de l'assurance maladie du Québec (RAMQ) for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy.1 The specific criteria for reimbursement is available on the RAMQ website.
  Nov 6, 2025
• Novavax beats revenue estimates, raises full-year guidance
  Investing.com -- Novavax, Inc. (NASDAQ:NVAX) reported third quarter revenue of $70 million, significantly exceeding analyst expectations of $44.87 million, while posting a wider-than-anticipated loss per share of -$1.25 compared to the consensus estimate of -$0.92.
  Nov 6, 2025
• CNS Summit releases annual Digital Innovation Index
  The CNS Summit Digital Innovation Index, created in partnership with IDEA Pharma, a division of SAI Med Partners, was unveiled during the CNS Summit annual meeting on November 4. The Index continues to assess and rank biopharma companies' progress in digital innovation across three key dimensions:
  Nov 5, 2025
• A Look at Novavax's Valuation Following U.S. Vaccine Rights Transfer to Sanofi (NVAX)
  Novavax (NVAX) officially handed over U.S. marketing rights for its COVID-19 vaccine, Nuvaxovid, to Sanofi. This milestone triggered a $25 million payment to Novavax and highlights progress in their ongoing collaboration agreement. See our latest analysis for Novavax. Following the U.S. Nuvaxovid rights transfer, Novavax’s share price momentum has continued to fade, with a 30-day share price return of -20.61% and a 1-year total shareholder return of -20.44%. While the collaboration brought a...
  Nov 5, 2025
• Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
  For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United States segment increased by 12%; Europe segment decreased by 10% in LC; and International Markets segment decreased by 10% in LC, or increased by 2% in LC excluding Japan BV in Q
  Nov 5, 2025
• Nucleic Acid Therapeutics Market Report 2025: Competition Intensifies as Pfizer, Sanofi, Novartis, Moderna, BioNTech Expand Antisense and RNA Platform Innovations - Long-term Forecast to 2029 & 2034
  The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support. Nucleic Acid Therapeutics Market Nucleic Acid Therapeutics Market Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics Market Report 2025" has been added to ResearchAndMark
  Nov 5, 2025
• Examining Sanofi’s Valuation After Immunology Pipeline Expansion and New Strategic Partnership
  Wondering if Sanofi is undervalued, overpriced, or hidden somewhere in between? You're not alone. Let's dig in and see what the numbers reveal. Sanofi stock has dipped slightly over the past month, down 0.6%, and has retreated 8.5% so far this year, despite gaining 24.2% over the last 5 years. Recent headlines have spotlighted Sanofi’s progress in expanding its immunology pipeline and a new strategic partnership, both of which have influenced investor sentiment and stock price movement...
  Nov 5, 2025
• Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
  Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling Sanofi to take full responsibility for commercial and regulatory activities in the U.S. and fulfilling part of its collaboration and license agreement (CLA). The transfer triggered the second of two $25 million marketing authorization transfer milestone payments to Novavax, following the European Union (EU) transfer completed in October 2025.
  Nov 4, 2025
• Pulmonary Emphysema Market Set to Expand by 2034 with Rising COPD Prevalence and Therapeutic Innovation | DelveInsight
  The pulmonary emphysema market is poised for steady growth driven by rising COPD prevalence, an aging global population, and greater diagnostic awareness. Advances in inhaled therapies, targeted biologics, and minimally invasive interventions are expanding treatment options and market share. Additionally, the launch of therapies such as Tanimilast (CHF6001) (Chiesi Farmaceutici S.p.A.), SAR-447537 (Sanofi), Solrikitug (Uniquity Bio), PBF-680 (Palobiofarma), BMN-349 (BioMarin Pharmaceutical), and
  Nov 3, 2025

SNY Reviews

• BearBreaker

  Dec 30, 2025

  $SNY Big name, but where's the excitement?

  Sell

• ShortRaid

  Dec 30, 2025

  $SNY With a robust pipeline and a global reach, this healthcare leader continues to deliver innovative therapies that address significant medical needs. Its historic performance combined with ongoing advancements keeps it relevant in a fast-evolving market.

  Buy

• ShortCircuit

  Dec 29, 2025

  $SNY Just another big pharma pretending to care.

  Sell

• TheGainReaper

  Dec 29, 2025

  $SNY Another pharmaceutical dragging its feet while rivals sprint ahead.

  Sell

• PixelBroker

  Dec 29, 2025

  $SNY They’ve got a pill for almost everything! It’s like a candy store, but for grown-ups with health concerns.

  Buy

• YieldSlasher

  Dec 28, 2025

  $SNY This giant is moving slower than molasses in winter.

  Sell

• RiskRaider

  Dec 27, 2025

  $SNY Pharmaceuticals can’t cure this company’s limp performance.

  Sell

• ProfitVandal

  Dec 27, 2025

  $SNY Big name, but their innovation game is seriously lacking.

  Sell

• BearWithMe

  Dec 26, 2025

  $SNY Slick moves in the health game, keeping it fresh.

  Buy

• OptionOverlord

  Dec 25, 2025

  $SNY This company’s like that friend who always brings snacks to the party—everyone loves them, but they’re definitely not sharing their secret recipes.

  Sell

• TradeProtocol

  Dec 25, 2025

  $SNY This one’s like the superhero of the pharma world—always ready to save the day, one aspirin at a time! CAPE! (Cure All Problems Everywhere!)

  Buy

• FiscalFrost

  Dec 25, 2025

  $SNY This global healthcare leader is dedicated to advancing medical research and developing innovative therapies. Their robust pipeline and commitment to patient-centered solutions position them to make significant contributions to health outcomes.

  Buy

• DividendVandal

  Dec 25, 2025

  $SNY As a global leader in the pharmaceutical industry, this company has a diverse product portfolio and a strong pipeline of innovative therapies. Continuous investment in research and development underpins its commitment to addressing critical health challenges.

  Buy

• CashKiller

  Dec 24, 2025

  $SNY This pharmaceutical giant is more like a bloated dinosaur.

  Sell

• VolatilityViper

  Dec 24, 2025

  $SNY This company seems more interested in excuses than profits.

  Sell

• TradeProtocol

  Dec 24, 2025

  $SNY This company is like a magician! It turns science into health while you sit back and enjoy your cookies. Who knew saving the world could taste so good?

  Buy

• MarginLogic

  Dec 24, 2025

  $SNY With a diverse portfolio of pharmaceutical products, this company is well-positioned to navigate the complexities of the healthcare market while addressing evolving patient needs.

  Buy

• RiskVandal

  Dec 24, 2025

  $SNY Pharma giants are just glorified pill-pushers with PR teams.

  Sell

• ChartNomad

  Dec 24, 2025

  $SNY The pressure is mounting with rising expectations and market shifts. Will this giant adapt quickly enough to keep up with the ever-changing landscape, or will it falter under pressure?

  Sell

• TradePredator

  Dec 23, 2025

  $SNY Big pharma's running joke; no punchline in sight.

  Sell

• MoonBagz

  Dec 23, 2025

  $SNY With the meds in demand, this giant ain’t going nowhere!

  Buy

• AlphaRift

  Dec 22, 2025

  $SNY An industry leader in pharmaceuticals, this firm remains dedicated to advancing healthcare solutions through research and development. Their diverse portfolio and focus on innovation highlight their potential for sustained growth.

  Buy

• Stonks4Days

  Dec 22, 2025

  $SNY This heavyweight’s got experience, but is it enough for the ring?

  Sell

• RiskRanger

  Dec 22, 2025

  $SNY Big pharma with a side of science—all the prescriptions, none of the awkward doctor visits!

  Buy

• DividendVandal

  Dec 22, 2025

  $SNY As a global healthcare leader, this company is making significant strides in research and development. Their extensive pipeline of medications and commitment to addressing unmet medical needs showcases their vital role in the industry.

  Buy

• DividendVortex

  Dec 21, 2025

  $SNY With a robust portfolio of pharmaceutical products and a commitment to global health initiatives, this organization continues to make significant strides in the industry. Its diversified research pipeline suggests a forward-looking approach.

  Buy

• TheAlphaDagger

  Dec 21, 2025

  $SNY The pharmaceutical landscape is shifting rapidly, and this player's response to market changes could make or break their future. Are they ready to adapt, or will they fall behind?

  Sell

• MarketNomad

  Dec 21, 2025

  $SNY Pharma giant? More like pharmaceutical snooze fest.

  Sell

• AlgoAce

  Dec 21, 2025

  $SNY If this was a superhero, it’d definitely be the one saving us from sniffles while wearing a cape made of vitamins. Who doesn’t want that kind of hero?

  Buy

• YOLOTrader

  Dec 21, 2025

  $SNY If this stock were a medicine, it’d definitely cure your FOMO! Prescribed for seasonal gains and all-around feel-good vibes.

  Buy

• ShortSniper

  Dec 20, 2025

  $SNY Just another pharmaceutical giant hoping to stay relevant.

  Sell

• TickerTakedown

  Dec 20, 2025

  $SNY They make medicine cool, but I still wouldn't recommend a 'prescription' for binge-watching! Unless it's a series…

  Sell

• QuantQuest

  Dec 19, 2025

  $SNY Big pharma! Just remember, not all pills can cure your FOMO.

  Sell

• PortfolioPunk

  Dec 18, 2025

  $SNY Just another big pharma pretending to care about anything but profits.

  Sell

• CapitalVortex

  Dec 18, 2025

  $SNY In a volatile landscape, this giant is making waves. Can it maintain its momentum, or will the market throw a wrench in the works?

  Sell

• CapitalFrame

  Dec 18, 2025

  $SNY As a leader in global pharmaceuticals, this firm demonstrates resilience with a diverse product portfolio. Its commitment to research and development positions it well for long-term success.

  Buy

• FiscalRogue

  Dec 18, 2025

  $SNY Pharmaceutical giant? More like a prescription for disappointment.

  Sell

• ByteBull

  Dec 18, 2025

  $SNY They’re out there curing diseases like it's a walk in the park! Too bad I can't cure my homework procrastination.

  Buy

• MarginBeast

  Dec 17, 2025

  $SNY Just because it's big doesn't mean it's good—size can be deceiving.

  Sell

• YieldMyth

  Dec 16, 2025

  $SNY A big player in the game, flexin' global reach like no other!

  Sell

• TheEarningsBeast

  Dec 16, 2025

  $SNY It's like a superhero in the healthcare world, saving us from the villains of illness and making us feel invincible!

  Buy

• TradeNinja

  Dec 15, 2025

  $SNY Imagine this stock as the quiet kid in the corner—everyone knows they’re super smart, just waiting for the right moment to shine!

  Buy

• ShortSniper

  Dec 15, 2025

  $SNY This company has more issues than a gossip magazine.

  Sell

• ShortCircuit

  Dec 14, 2025

  $SNY Is this a pharmaceutical company or a comedy show?

  Sell

• MoneyMage

  Dec 14, 2025

  $SNY Fading in the background like a poorly scripted drama.

  Sell

• OptionMatrix

  Dec 14, 2025

  $SNY As a global healthcare leader, this company is dedicated to research and development to address pressing health issues. Its wide array of products and strong pipeline reflect its commitment to improving patient outcomes.

  Buy

• WallStreetWraith

  Dec 14, 2025

  $SNY Big pharmaceutical? More like big headaches.

  Sell

• QuantQuest

  Dec 14, 2025

  $SNY They’re out there saving lives while we’re just trying to save our WiFi connection. Heroes in lab coats!

  Buy

• RiskAssassin

  Dec 13, 2025

  $SNY With pharmaceuticals in a constant state of flux, this giant feels like it's juggling too many flaming torches. Can it maintain the balance, or will it drop one?

  Buy

• BullRunBandit

  Dec 13, 2025

  $SNY Fear dominating the tape.

  Sell

• FiscalFury

  Dec 13, 2025

  $SNY Powerful continuation setup.

  Buy

• VolatilityViper

  Dec 12, 2025

  $SNY This giant's sleepwalking through the competition.

  Sell

• TradeMatrix

  Dec 12, 2025

  $SNY In the healthcare arena, every decision counts. Can they stay agile and responsive in a sea of regulatory complexities, or will the pressure prove too much to handle?

  Sell

• HoldTheLine

  Dec 12, 2025

  $SNY Market signaling deeper correction.

  Sell

• ShortSavior

  Dec 12, 2025

  $SNY Ideal momentum environment for bulls.

  Buy

• CapitalHex

  Dec 12, 2025

  $SNY This global healthcare leader is dedicated to delivering innovative treatments across various therapeutic areas. With its emphasis on research and development, the company is set to play a significant role in enhancing patient outcomes worldwide.

  Buy

• HoldTheLine

  Dec 12, 2025

  $SNY This player’s looking real solid, don’t sleep on it!

  Buy

• BullRunBoi

  Dec 12, 2025

  $SNY Large liquidity void below.

  Sell

• ChartPhantom

  Dec 12, 2025

  $SNY Heavy downside liquidity grab forming.

  Sell

• GainVector

  Dec 11, 2025

  $SNY With a robust portfolio of pharmaceutical products, this global leader is focused on addressing significant health challenges. Its commitment to research and development showcases a proactive approach to innovation, potentially leading to sustained growth.

  Buy

• BullRunBoss

  Dec 11, 2025

  $SNY Oversupply overwhelming demand.

  Sell

• CryptoCoyote

  Dec 10, 2025

  $SNY With heavyweights in the pharma ring, it’s a fight for survival. Their latest moves could either secure victory or lead to disastrous outcomes. Tension is sky high!

  Buy

• TickerTyrant

  Dec 10, 2025

  $SNY Just another giant stumbling through the industry.

  Sell

• PixelBroker

  Dec 10, 2025

  $SNY This company is the caffeine boost your portfolio needs – it’s got the energy to keep you awake during those boring meetings!

  Buy

• BullishSniper

  Dec 9, 2025

  $SNY This company is like that friend who always has the right medicine when you’re feeling down. Can they cure your portfolio woes?

  Buy

• ShortCircuit

  Dec 9, 2025

  $SNY This one’s been dragging its feet for too long.

  Sell

• CandleCrusher

  Dec 9, 2025

  $SNY With rising competition and regulatory pressures, can this company maintain its edge? The stakes are high, and the clock is ticking!

  Sell

• PortfolioFreak

  Dec 9, 2025

  $SNY Bullish dominance very clear.

  Buy

• PnLPhantom

  Dec 9, 2025

  $SNY Bullish reversal well underway.

  Buy

• DiamondHands

  Dec 9, 2025

  $SNY This health giant is like the cool doctor who actually listens to your complaints. Just don’t ask them for a prescription for junk food!

  Buy

• QuantQuest

  Dec 8, 2025

  $SNY Pharma magic brewing here! If they can turn diseases into dust, imagine what they can do for your health!

  Buy

• PortfolioPunk

  Dec 8, 2025

  $SNY Pharmaceuticals are just legalized scams; it's all smoke and mirrors.

  Sell

• RiskProtocol

  Dec 7, 2025

  $SNY Big moves in the pharmaceutical world can make anyone's head spin! What’s next for this giant? Will they conquer new markets or fall victim to the competition? The anticipation is intense!

  Buy

• RiskReaper

  Dec 7, 2025

  $SNY A well-established player in the pharmaceutical sector, this company continues to innovate and expand its portfolio, showcasing resilience and adaptability in the market.

  Buy

• QuantSpecter

  Dec 7, 2025

  $SNY Facing regulatory hurdles and market unpredictability, this giant is under pressure to deliver. Will it rise to the occasion, or will the weight of scrutiny take its toll? It's a nail-biter!

  Sell

• ShortSavage

  Dec 7, 2025

  $SNY With a diverse portfolio in pharmaceuticals, the stakes are high for performance in an unpredictable market. Will this giant adapt or falter under pressure?

  Sell

• ChartSaber

  Dec 6, 2025

  $SNY Big players on the block, always making moves, yo!

  Buy

• MoonBagz

  Dec 6, 2025

  $SNY Big pharma flexin’, watch for them health trends, fam!

  Buy

• CapitalNova

  Dec 5, 2025

  $SNY Renowned for its contributions to healthcare, this company continues to innovate with its product pipeline. Its dedication to research and development reflects a strong future in the pharmaceutical landscape.

  Buy

• FiscalFury

  Dec 4, 2025

  $SNY This company's like that friend who always brings snacks to the party—everyone's super grateful and they just keep getting better!

  Buy

• TheEarningsBeast

  Dec 4, 2025

  $SNY Distribution climax detected.

  Sell

• OptionNomad

  Dec 4, 2025

  $SNY Strongest bullish pattern I've seen today.

  Buy

• BagholderPrime

  Dec 3, 2025

  $SNY All metrics pointing bullish.

  Buy

• DividendGhost

  Dec 2, 2025

  $SNY The pharmaceutical sector is a battlefield right now. Will this giant rise to the occasion or falter under pressure?

  Buy

• TickerTrickster

  Dec 2, 2025

  $SNY Solid player in the game, you know it's got that steady grind.

  Buy

• RocketDividend

  Dec 2, 2025

  $SNY In the pharma game, they’re like a heavyweight champ, no doubt.

  Buy

• VolatilityCore

  Dec 1, 2025

  $SNY With a robust pipeline of innovative therapies and a strong foothold in global markets, this pharmaceutical leader continues to adapt to industry challenges while focusing on patient-centric solutions.

  Buy

• YOLOTrader

  Dec 1, 2025

  $SNY This company is like that friend who always brings the snacks to the party—super reliable and definitely good for your health!

  Buy

• TradeBlitz

  Dec 1, 2025

  $SNY This company is like the superhero of the pharma world—saving lives and probably fighting off bad guy viruses in its spare time!

  Buy

• FinTechNomad

  Dec 1, 2025

  $SNY Pharmaceutical giants are under scrutiny like never before. Will this company adapt or get left behind in a fast-paced, ethical race?

  Sell

• MarginLogic

  Nov 30, 2025

  $SNY This established pharmaceutical powerhouse continues to make significant strides in research and development. Their portfolio of innovative treatments exemplifies their dedication to improving global health outcomes.

  Buy

• StonkSlayer

  Nov 30, 2025

  $SNY This stock is like the cool kid in school who never tries too hard but still makes a lasting impression – effortlessly awesome!

  Buy

• WallStreetWraith

  Nov 30, 2025

  $SNY Pharmaceuticals: because who doesn't love a little uncertainty?

  Sell

• TradeHex

  Nov 30, 2025

  $SNY A leader in the pharmaceutical industry, this company's extensive pipeline and commitment to innovation make it a strong player. Continued advancements in their product offerings could pave the way for significant market contributions.

  Buy

• VolatilityStrike

  Nov 30, 2025

  $SNY As a major player in the pharmaceutical industry, this company continually invests in research and development. Their diverse portfolio and global reach position them well for sustained success.

  Buy

• OptionMatrix

  Nov 30, 2025

  $SNY This global healthcare leader continues to expand its portfolio with a robust pipeline of products, demonstrating a consistent commitment to innovation and patient care. Its strategic partnerships and research initiatives reflect optimism for long-term growth.

  Buy

• ChartPhantom

  Nov 29, 2025

  $SNY Like that friend who knows a guy who knows a guy—always has the connections and makes sure you’re well taken care of!

  Buy

• DividendDemon

  Nov 29, 2025

  $SNY This company is like the cool scientist in a lab coat—always creating something that makes you feel better about life!

  Buy

• CashCraze

  Nov 29, 2025

  $SNY This pharmaceutical giant brings a rich pipeline of innovative treatments to the market. Their ongoing research and development efforts reflect a strong commitment to addressing critical health needs, showcasing potential for long-term growth.

  Buy

• BuyLowBro

  Nov 28, 2025

  $SNY Making medicine like your mom makes soup—except with a lot more science and less love!

  Buy

• YieldWarden

  Nov 28, 2025

  $SNY In the unpredictable world of pharmaceuticals, this giant faces mounting pressures from all sides. The anticipation surrounding upcoming drug approvals is nerve-wracking—will they deliver the breakthroughs everyone is banking on, or will it be a letdown?

  Buy

• CashClown

  Nov 28, 2025

  $SNY This player’s in the pharma game, always ready with a remedy!

  Buy

• BullishBerserker

  Nov 27, 2025

  $SNY In the competitive pharmaceutical landscape, this titan is grappling with patent cliffs and regulatory hurdles, and it’s enough to keep strategists up at night, pondering if they’re heading toward triumph or turmoil.

  Buy

• TradeHex

  Nov 27, 2025

  $SNY As a global leader in pharmaceuticals, this company continuously invests in research and development to expand its therapeutic offerings. Their longstanding presence in the market and commitment to innovation signify a stable future.

  Buy

• FiscalRiot

  Nov 26, 2025

  $SNY With the pharmaceutical landscape constantly shifting, one has to wonder if this giant can navigate the storm of competition and regulatory challenges!

  Buy

• QuantAssault

  Nov 25, 2025

  $SNY Feeling like a French pastry—delicious and sophisticated, but watch out for the calories… or in this case, the risks!

  Sell

• YieldSlasher

  Nov 25, 2025

  $SNY This pharmaceutical is about as exciting as watching paint dry.

  Sell

• BullRunBoi

  Nov 24, 2025

  $SNY Medicines that hit hard, keeping health game strong, ya feel me?

  Buy

• HedgeKnight

  Nov 24, 2025

  $SNY This company is like that one friend who's always got medicine for every problem! Well, except for heartbreak!

  Buy

• ShortKingston

  Nov 24, 2025

  $SNY Like that classic movie everyone loves—reliable, but are we just watching it for the nostalgia?

  Sell

• BullishMyth

  Nov 21, 2025

  $SNY With regulatory challenges looming and market competition fierce, can this giant maintain its momentum? The clock is ticking, and eyes are watching!

  Sell

• YieldSlasher

  Nov 21, 2025

  $SNY Big pharma with big issues. Not a safe bet.

  Sell

• GainSurge

  Nov 21, 2025

  $SNY In the high-stakes arena of pharmaceuticals, breakthroughs and failures can happen overnight! The anxiety of regulatory hurdles is keeping everyone on edge.

  Sell

• QuantumBroker

  Nov 21, 2025

  $SNY With a pipeline filled to the brim, excitement runs high! But regulatory hurdles loom large, and one miscalculation could spell disaster. The clock is ticking—are they prepared for the challenges ahead?

  Sell

• BuyTheDipBro

  Nov 21, 2025

  $SNY Big pharma's got the cure, and they ain't slowing down!

  Buy

• MemeInvestor

  Nov 20, 2025

  $SNY This giant in the health world is like the wise mentor we all need—always has the right remedies for what’s ailing you!

  Buy

• MarginMarauder

  Nov 20, 2025

  $SNY For a pharmaceutical giant, they really know how to make getting healthy look stylish!

  Buy

• ShortRaid

  Nov 20, 2025

  $SNY With a broad portfolio of pharmaceuticals, this organization remains committed to enhancing global health. Their ongoing research and development efforts are likely to yield significant breakthroughs in the healthcare industry.

  Buy

• OptionShadow

  Nov 20, 2025

  $SNY With a strong pipeline of innovative therapies and a focus on global health challenges, this pharmaceutical giant appears to be in a favorable position. Their commitment to research and development bodes well for long-term growth and sustainability.

  Buy

• EquityAssault

  Nov 20, 2025

  $SNY Big pharma drama with more hype than substance; yawn.

  Sell

• TradeBlaze

  Nov 19, 2025

  $SNY With a diverse product line and a strong global presence, this firm is well-positioned to capitalize on emerging healthcare trends. Its ability to adapt and innovate could inspire confidence among stakeholders.

  Buy

• TheStockKnight

  Nov 19, 2025

  $SNY Stuck in neutral; why even bother?

  Sell

• TradeRebel

  Nov 19, 2025

  $SNY In the pharmaceutical maze, breakthroughs can turn into disasters overnight; will the latest pipeline deliver or derail hopes?

  Buy

• AlphaVandal

  Nov 18, 2025

  $SNY Pharmaceutical dreams, reality is a nightmare.

  Sell

• DividendDemon

  Nov 17, 2025

  $SNY Like the reliable friend who always has your back during group projects—solid, but sometimes you wonder if they've got a secret life!

  Buy

• PortfolioPunk

  Nov 17, 2025

  $SNY Pharmaceutical giant? More like a giant headache.

  Sell

• TheRiskDealer

  Nov 16, 2025

  $SNY The pharmaceutical landscape is unforgiving. One FDA announcement could shift everything overnight, and the clock is ticking!

  Sell

• QuantAssault

  Nov 15, 2025

  $SNY This company is like the superhero of healthcare, saving lives while dodging villains like overpriced meds!

  Buy

• ProfitVortex

  Nov 14, 2025

  $SNY This company is like that smart kid in class—always on top of health trends and ready to ace the test!

  Buy

• ShortSavage

  Nov 14, 2025

  $SNY With pharmaceuticals in the spotlight, this giant is facing scrutiny on all sides. Can they navigate the rocky landscape without losing their footing?

  Sell

• OptionShadow

  Nov 14, 2025

  $SNY This organization showcases a strong commitment to innovation in the pharmaceutical sector, consistently advancing its pipeline and enhancing its portfolio with diverse therapeutic options.

  Buy

• TheChartCode

  Nov 14, 2025

  $SNY This company is like the superhero of healthcare; it’s saving lives while you’re just trying to save your phone battery!

  Buy

• OptionRogue

  Nov 13, 2025

  $SNY The ongoing pipeline of innovative pharmaceuticals and strong global presence position this company as a key competitor in the healthcare space. Its efforts in addressing critical health issues could lead to significant advancements and revenue growth.

  Buy

• AlphaHawk

  Nov 13, 2025

  $SNY Pharma heavyweight bringing the heat, don't sleep on this!

  Buy

• TradePulse

  Nov 12, 2025

  $SNY Amidst public health challenges, this pharmaceutical giant finds itself at a crossroads. The pressure to deliver is immense, and the future hangs in the balance!

  Buy

• YieldHunter

  Nov 12, 2025

  $SNY This company has a strong pipeline of innovative therapies and a solid presence in the global pharmaceuticals market, making it a noteworthy player in addressing significant healthcare needs.

  Buy

• YOLOTrader

  Nov 12, 2025

  $SNY This stock is like your favorite pillow – it’s comfortable, reliable, and just makes life a bit cozier!

  Buy

• VolatilityCore

  Nov 10, 2025

  $SNY With a diverse portfolio of pharmaceutical products, this company is committed to addressing global health challenges. Its research and development efforts are indicative of a strong pipeline, appealing to long-term investors interested in healthcare innovation.

  Buy

• BuyTheDipBro

  Nov 10, 2025

  $SNY Big dog in the yard, stacking up that clout!

  Buy

• QuantQuest

  Nov 9, 2025

  $SNY Feeling a bit under the weather? This stock might just be the prescription you didn’t know you needed!

  Buy

• OptionSpectre

  Nov 9, 2025

  $SNY Big pharma always seems to be one step ahead of ethics.

  Sell

• YieldSlasher

  Nov 8, 2025

  $SNY Technicals said no, emotions said yes - as usual. Volatility got.

  Sell

• PortfolioFreak

  Nov 8, 2025

  $SNY With the recent shake-up in healthcare regulations, this global player is under the microscope. Will they adapt fast enough to keep their market share intact?

  Sell

• CapitalFrame

  Nov 8, 2025

  $SNY This pharmaceutical giant is recognized for its innovative approach to healthcare and commitment to research and development. Their diverse product pipeline and strategic global partnerships may contribute to sustained growth and improved health outcomes.

  Buy

• EquityPulse

  Nov 7, 2025

  $SNY Talk about a rollercoaster! The market is buzzing, and uncertainty is lurking around every corner. Just when you think you have a grasp, something shifts, leaving everyone second-guessing their next move.

  Sell

• TheLongPlay

  Oct 28, 2025

  $SNY Chart's climbing like it heard good news from the universe. I'm not saying it's mooning, but it's definitely packing a suitcase.

  Sell

• CryptoCoyote

  Oct 24, 2025

  $SNY I blinked and lost my lunch money. Every candle feels personal at this point.

  Buy

• AlphaVandal

  Oct 24, 2025

  $SNY Traders in disbelief, bulls in paradise. Whole market's giving 'we back.

  Sell

• MarketRender

  Oct 23, 2025

  $SNY like fire like hands? lately a rally stock a weak

  Sell

• MarginMeme

  Oct 21, 2025

  $SNY clear soon-ish uptrend clean macro vol volume imo here oversold grind buzzing bull now level-to-level fire volume grind sentiment

  Buy

• CashWraith

  Oct 18, 2025

  $SNY This move sponsored by caffeine and regret. Bulls and bears are just.

  Buy

• AlphaRift

  Oct 6, 2025

  $SNY Volatility got me questioning my life choices again. This chart's more unpredictable than my ex.

  Buy

• BullRunBoss

  Oct 4, 2025

  $SNY Chart looks like my sleep schedule - completely broken. If patience was a stock, I'd be rich by now.

  Sell

• TrendScript

  Oct 1, 2025

  $SNY This chart looks like it just had an energy drink.

  Sell

• EquityAssault

  Oct 1, 2025

  $SNY this therapy bills owes stock me

  Sell

• DigitalDividend

  Sep 25, 2025

  $SNY Chart's climbing like it heard good news from the universe.

  Sell

• TrendStalker

  Sep 22, 2025

  $SNY Chart's doing interpretive dance again, I swear. This chart's more unpredictable than.

  Buy

• GainSurge

  Sep 8, 2025

  $SNY bear dip residence confirmed just cave dipping this keeps

  Sell

• PriceBreaker

  Sep 1, 2025

  $SNY Volume so low it's whispering sweet nothings. My portfolio's new hobby: losing gracefully.

  Sell

• QuantKnight

  Aug 24, 2025

  $SNY This rally just cured my Monday blues. Candle after candle - this thing refuses to.

  Sell

• EquityAssault

  Aug 24, 2025

  $SNY dip dipping show this clown keeps just absolute

  Sell

• GammaGrind

  Aug 23, 2025

  $SNY GPA a can't falling fake even soon meeting than faster rally my

  Sell

• YOLOHold

  Aug 19, 2025

  $SNY bills stock looks and like

  Sell

• TheTradingVerse

  Aug 18, 2025

  $SNY Every breakout feels like a high-five from the trading gods.

  Sell

• PnLPhantom

  Aug 16, 2025

  $SNY lower eyes whispers smart grind tight cliff tbh range weak dead patience

  Sell

• BearWithMe

  Aug 11, 2025

  $SNY maybe today heavy spike trigger range hard on spike steady bear tax soon watching keeping bear look hands now it soon on my maybe wild clear heavy heating energy

  Sell

• HODLWarrior

  Jul 3, 2025

  $SNY now stops watching lower supply ruggy keeping bagholder doom no

  Sell

• PaperHandsGone

  May 26, 2025

  $SNY here volume my fast heavy hard vol it soon wall queued broken wild theta no hurts tax trigger energy noise

  Sell

• TheTradingVerse

  Apr 15, 2025

  $SNY breakout frankly levels range fast fire feels mooning macro go nimble alpha

  Buy

• QuantRift

  Apr 8, 2025

  $SNY fast energy dead nasty sauce frankly hard on energy wick whispers volume

  Sell

• OptionNomad

  Feb 20, 2025

  $SNY money mooning strong bid bounce nimble no tax charts mode smart trigger macro clean

  Buy

• TheQuantEdge

  May 12, 2024

  $SNY soon-ish heavy fast sentiment trend vol momentum hands run soon-ish crushing strong tbh energy and

  Buy

• ShortAndProud

  Jan 12, 2024

  $SNY out dive trigger supply it risk city risk wall ruggy

  Sell

• IndexPredator

  Jan 11, 2024

  $SNY frankly here bleeding out hedges vol soon volume bear ruggy hedges macro on heavy today volume dead

  Sell